How did I misrepresent you? You said the CR was excellent...

How did I misrepresent you? You said the CR was excellent achievement and then went on to say on the same post that management are increasing dosage as they don't see any efficacy. Any CR so early in Ph1 clinical trial is excellent which is why even the lead presenter mentioned this in the Conference (you tried to dismiss this in another post before I sent you the Tweet from him) and why the FDA granted Fast Track designation and ODD so early. Fast Track designation can be granted with lab studies on animals???? Must admit, I've never heard this before.

I'm not sure what your point about CG0070, they are currently in Ph3 clinical trial which is very expensive to conduct so what were their development funding and stage before this in the last 12 years?????

Azer-Cel's market growth will be whether they can expand to other treatment for liquid cancer but the acquisition was mainly based on combining CD19 with CF33 which is why the clinical trial for OASIS commenced to target other solid tumour which CF33 can't alone.

IMU's short volume has always been very high since entering the ASX300 which is why the stock has and is still being traded but they will need to eventually cover depending on the fundamental news. Look at the short volume for MSB and their pps in the last 12 months, the market isn't always right . What news are the big investors waiting for is the question........